Imara-Logo-Color-RGB.jpg
Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights
08 mars 2022 07h00 HE | Imara, Inc.
BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara to Present at Upcoming Investor Conferences
03 sept. 2021 07h00 HE | Imara, Inc.
BOSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sickle Cell Disease
05 août 2021 07h15 HE | Imara, Inc.
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara to Webcast Conference Call of Second Quarter 2021 Financial Results and Business Highlights
30 juil. 2021 07h00 HE | Imara, Inc.
BOSTON, July 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara Announces Pricing of Public Offering
13 juil. 2021 22h58 HE | Imara, Inc.
BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to...
Imara-Logo-Color-RGB.jpg
Imara Announces Appointment of Laura A. Williams, M.D., MPH to Board of Directors
30 juin 2021 07h00 HE | Imara, Inc.
BOSTON, June 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
11 juin 2021 03h00 HE | Imara, Inc.
Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687 Interim open-label extension clinical trial...
Imara-Logo-Color-RGB.jpg
Imara Reports First Quarter 2021 Financial Results and Business Highlights
11 mai 2021 07h00 HE | Imara, Inc.
On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021 Completed enrollment in the...
Imara-Logo-Color-RGB.jpg
Imara to Webcast Conference Call of First Quarter 2021 Financial Results and Business Highlights
04 mai 2021 07h00 HE | Imara, Inc.
BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...